《公司業績》石四藥(02005.HK)首季純利按年增56.5%至約3億元
石四藥集團(02005.HK)公佈,截至今年3月底止首季未經審覈營業額按年增加40.8%至約17.33億元,純利按年增加56.5%至約3.03億元,主要原因是原料藥營業額按年大增267.1%,當中咖啡因系列產品營業額大增逾7倍,加上銷售費用率有所下降及期內並無因授出購股權產生的費用。
期內,毛利率約爲58.8%,按年下降5.2個百分點,主要原因是原料藥所佔營業額的比例有所提升,而原料藥的毛利率低於藥物製劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.